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Abstract
Introduction It has been demonstrated that leukemia inhibitory
factor (LIF) induces epithelium apoptosis through Stat3
activation during mouse mammary gland involution. In contrast,
it has been shown that this transcription factor is commonly
activated in breast cancer cells, although what causes this effect
remains unknown. Here we have tested the hypothesis that
locally produced LIF can be responsible for Stat3 activation in
mouse mammary tumors.
Methods The studies were performed in different tumorigenic
and non-tumorigenic mammary cells. The expression of LIF and
LIF receptor was tested by RT-PCR analysis. In tumors, LIF and
Stat3 proteins were analyzed by immunohistochemistry,
whereas Stat3 and extracellular signal-regulated kinase (ERK)1/
2 expression and phosphorylation were studied by Western blot
analysis. A LIF-specific blocking antibody was used to
determine whether this cytokine was responsible for Stat3
phosphorylation induced by conditioned medium. Specific
pharmacological inhibitors (PD98059 and Stat3ip) that affect
ERK1/2 and Stat3 activation were used to study their
involvement in LIF-induced effects. To analyze cell survival,
assays with crystal violet were performed.
Results High levels of LIF expression and activated Stat3 were
found in mammary tumors growing in vivo and in their primary
cultures. We found a single mouse mammary tumor cell line,
LM3, that showed low levels of activated Stat3. Incidentally,
these cells also showed very little expression of LIF receptor.
This suggested that autocrine/paracrine LIF would be
responsible for Stat3 activation in mouse mammary tumors. This
hypothesis was confirmed by the ability of conditioned medium
of mammary tumor primary cultures to induce Stat3
phosphorylation, activity that was prevented by pretreatment
with LIF-blocking antibody. Besides, we found that LIF
increased tumor cell viability. Interestingly, blocking Stat3
activation enhanced this effect in mammary tumor cells.
Conclusion LIF is overexpressed in mouse mammary tumors,
where it acts as the main Stat3 activator. Interestingly, the
positive LIF effect on tumor cell viability is not dependent on
Stat3 activation, which inhibits tumor cell survival as it does in
normal mammary epithelium.
Introduction
The pleiotropic cytokine leukemia inhibitory factor (LIF) is a
secreted 38 to 67 kDa glycoprotein first named for its ability
to induce macrophage differentiation in the murine myeloid
leukemic cell line M1 [1]. This factor has been detected in a
variety of adult mouse tissues and displays different biological
activities, including effects on bone metabolism, inflammation,
neural development and embryogenesis [2]. A potential role
for LIF in the pathogenesis of human breast cancer is indi-
cated by its expression in breast cancer cells [3,4], which can
C/EBP = CCAAT-enhancer-binding protein; CM = conditioned medium; ER = estrogen receptor; ERK = extracellular signal-regulated kinase; FBS 
= fetal bovine serum; HDT = hormone-dependent tumor; HIT = hormone-independent tumor; IL = interleukin; JAK = Janus kinase; LIF = leukemia 
inhibitory factor; LIF-D = secreted 'free' form of LIF; LIF-M = extracellular matrix-associated form of LIF; LIF-R = leukemia inhibitory factor receptor; 
MAPK = mitogen-activated protein kinase; MEM = minimal essential medium; MEK = MAPK/ERK kinase; MMTV = mouse mammary tumor virus; PBS 
= phosphate-buffered saline; PR = progesterone receptor; pY = tyrosine-phosphorylated; RT-PCR = reverse transcriptase-mediated polymerase 
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be modulated by progestins and antiprogestins [5], and by its
capacity to induce the proliferation of several estrogen-
dependent (MCF-7 and T47D) and estrogen-independent
(SK-BR3 and BT20) breast cancer cell lines as well as fresh
breast carcinoma cells [4,6]. In spite of these data, little is
known about the relevance of LIF for mammary tumor develop-
ment in vivo.
Biological functions of LIF are mediated by the formation of a
cell surface LIF receptor complex between the low-affinity LIF
receptor (LIF-R) and a gp130 subunit [7,8]. All the known
receptors that contain gp130 have Janus kinase (JAK) kinases
(tyrosine kinases) bound to their intracellular tails [9]. After lig-
and-mediated receptor assembly, the JAKs become activated
and phosphorylate cytoplasmic proteins called signal trans-
ducer and activators of transcription (Stats). The activated
Stats then dimerize, translocate to the nucleus, and participate
in transcriptional regulation by binding to specific DNA sites. It
has been reported that among the seven members of the Stat
family, Stat3 is the major mediator of gp130 signals [10,11].
In the normal mouse mammary gland, Stat3 is pro-apoptotic
and a crucial mediator of post-lactational regression. Mam-
mary local factors stimulate the phosphorylation of Stat3 dur-
ing involution [12], and mammary glands of Stat3 conditional
knockout mice showed a suppression of epithelial apoptosis
that led to a marked delay in mammary gland involution [13].
However, elevated Stat3 tyrosine phosphorylation and DNA-
binding activity have been reported in breast cancer cell lines.
In addition, inhibition of the activation of Stat3 blocked the pro-
liferation and survival of those cancer cells [14-16].
It has been established that LIF is the physiological activator of
Stat3 during mammary gland involution and has a principal
role in the apoptotic process [17,18]. In addition, the capacity
of LIF to induce Stat3 phosphorylation has been demon-
strated in several different experimental models [19-23]. How-
ever, no linkage has yet been made between LIF expression
and Stat3 activation in mammary tumors. To address this
issue, in the present study we evaluated LIF expression and its
ability to induce Stat3 tyrosine phosphorylation in mouse
mammary tumors. Taking into account the drastic difference in
the significance of activation of this transcription factor in neo-
plastic and normal mammary cells, various tumor lines were
assayed and compared with the non-tumorigenic HC11 cell
line. We also studied LIF expression and its ability to induce
Stat3 activation in mouse mammary tumor models with differ-
ent grades of differentiation and malignancy: the non-meta-
static mouse mammary tumor virus (MMTV)-induced hormone-
dependent and hormone-independent neoplasias (HDTs and
HITs, respectively) [24,25] and the poorly differentiated highly
metastatic LM3 mammary tumor line [26].
Materials and methods
Animals
Female BALB/c mice from our mouse colony, 8 to 12 weeks
in age and 20 to 25 g in weight, were used throughout. They
were housed four per cage in conditioned rooms at 20 ± 2°C,
kept under an automatic 12 hours light/12 hours darkness
schedule, and given pellets and tap water ad libitum. All animal
studies were conducted in accordance with the NIH Guide for
the Care and the Use of Laboratory Animals.
Tumors and cell lines
The tumors, primary cultures and cell lines used are described
in Table 1.
Tumors growing in vivo were removed from mice before reach-
ing 1 cm3, then cut into fragments and processed for the dif-
ferent experimental procedures.
Cell culture assays
HC11 cells were maintained in growth medium (RPMI 1640
medium augmented with 10% fetal bovine serum (FBS; Invit-
rogen, Carlsbad, CA, USA), 5 μg/ml insulin (Sigma, Saint
Louis, MO, USA) and 2 mM glutamine (Hyclone). MCF-7 and
NMuMG cells were purchased from the American Type Cul-
ture Collection (Manassas, VA, USA), cultured as recom-
mended and supplemented with 10% FBS. SCp2 cells were
grown in Dulbecco's modified Eagle's medium/F-12 (Invitro-
gen) supplemented with 2% FBS and 5 μg/ml insulin. LM3
and LMM3 were cultured in MEM (Hyclone), supplemented
with 5% FBS (Invitrogen). All cell lines were cultured with anti-
biotic-antimycotic (100 units/ml penicillin G sodium, 100 μg/
ml streptomycin sulfate, 250 ng/ml amphotericin B as Fungi-
zone (Invitrogen)) at 37°C in a humidified atmosphere with 5%
CO2 in air.
Primary cultures
MMTV(LA)-induced tumor primary cultures (TPCs) were pre-
pared from HITs (that are, estrogen receptor-negative, proges-
terone receptor-negative (ER-PR-) neoplasias) (see Table 1).
Tumor pieces were washed in MEM with antibiotic-antimycotic
and passed through a nylon mesh. Sediment was resus-
pended in 20 ml of MEM containing 1% FBS and allowed to
precipitate for 20 minutes. The liquid phase of the suspension
was removed and cells were plated into 60 mm tissue culture
dishes or six-well plates. Cells were cultured in MEM contain-
ing 1% FBS and 10 ng/ml epidermal growth factor(Sigma
Aldrich, Saint Louis, MO, USA); when the cells had grown to
near confluence (3 to 4 days) they were rinsed with PBS and
incubated in MEM containing 1% FBS for 24 to 36 hours
before experimental treatments. Culture dishes and plates
were precoated by incubating them for 1 hour at room temper-
ature (18–22°C) with 50 μg/ml collagen in 0.02 M acetic acid
(rat tail collagen, type 1; Becton Dickinson Labware, Franklin
Lakes, NJ). The remaining solution was carefully aspirated and
then rinsed with PBS. For the preparation of conditionedAvailable online http://breast-cancer-research.com/content/9/5/R69
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medium (CM), established primary cultures were grown in
serum-free MEM for 15 hours and then in MEM containing 1%
FBS for 2 days before the supernatant was collected. CM was
then mixed with fresh medium to final proportions of 30%,
50% and 80%.
Biological and chemical reagents
Recombinant murine LIF (Sigma Aldrich) concentration is indi-
cated in each experiment. Recombinant murine IL-6 (Sigma
Aldrich) was used at 80 ng/ml. For neutralization of LIF, 1 ml
of CM was incubated with 0.8 μg of anti-mLIF neutralizing anti-
body (R&D Systems, Minneapolis, MN, USA) at room temper-
ature for 1 hour before cell treatment [27]. To inhibit
extracellular signal-regulated kinase (ERK)1/2 activbation
serum-starved HC11 cells were pretreated for 1 hour with 30
μM PD98059 (Calbiochem, San Diego California) or with
vehicle (1% v/v dimethyl sulfoxide) and then treated with LIF
for 5 minutes (for Western blot analysis) or 72 hours (for cell
viability assays). Treatment with Src inhibitor (PP2; Calbio-
chem) was performed as described previously [28]. In brief,
HC11 were starved for 1 hour and preincubated with 30 μM
PP2 for 15 minutes before treatment with LIF for 5 minutes. In
order to inhibit Stat3 activation, cell cultures were pretreated
with 1 mM Stat3-specific inhibitory peptide (Stat3ip; Calbio-
chem) 1 hour before stimulation with LIF for the indicated
periods.
Morphological and immunohistochemical studies
Tumors and normal mammary glands were fixed in 10% buff-
ered formalin and embedded in paraffin by using standard pro-
cedures [17]. In brief, after paraffin sections had been
dewaxed, they were rehydrated and either stained with hema-
toxylin and eosin or used for immunohistochemical studies. LIF
immunohistochemistry was performed as described [17] with
a polyclonal mouse LIF antibody (SC-1336). Stat3 immunohis-
tochemistry was conducted with a polyclonal rabbit anti-Stat3
antibody (SC-482) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA). Detections were performed with the Vectos-
tain Elite ABC immunoperoxidase system (Vector Laborato-
ries, Burlingame, CA, USA) in accordance with the
manufacturer's instructions with diaminobenzidine (Dako,
Carpinteria, CA, USA) as chromogen. LIF and Stat3 immunos-
taining were qualitatively evaluated by: (1) the presence or
absence of staining; (2) the type of structure with positive
staining and (3) the pattern and/or cellular localization of stain-
ing. Negative controls were performed by replacing the pri-
mary antibody with normal rabbit serum.
Immunofluorescence
HC11 were cultured on Lab-tek chamber slides (NUNC,
Rochester, NY, USA) for 48 hours, then preincubated with
Stat3 inhibitor peptide for 1 hour and treated with LIF (50 ng/
ml) for 30 minutes. After that, cells were fixed in 4% parafor-
maldehyde for 25 minutes at room temperature, washed with
PBS and preincubated at room temperature for 5 minutes with
PBS-based blocking buffer containing 0.1% SDS and 3%
bovine serum albumin. After being rinsed with PBS, the cells
were incubated with a 1:100 dilution of rabbit polyclonal anti-
Stat3 antibody (SC-482, Santa Cruz Biotechnology) in the
same blocking buffer. After being washed with PBS, cells
Table 1
Tumors, primary cultures and cell lines used in the experiments in this paper
Source Description References
Tumors and primary cultures
HDTs MMTV(LA)-induced HDTs growing in vivo [24,25,31]
HITs MMTV(LA)-induced HITs growing in vivo [24,25,31]
TPC Primary cultures derived from HITs
LM3 tumors Poorly differentiated adenocarcinomas derived from LM3 cells implanted subcutaneously in 
BALB/c mice
Cell lines
LM3 Cell line established from a spontaneous mammary tumor in BALB/c mouse [47]
LMM3 Cell line derived from a highly metastatic mammary tumor in BALB/c mouse [47]
HC11 Normal mouse mammary epithelial cell line [50,51]
SCP2 Normal mouse mammary epithelial cell line [52]
NMuMG Normal mouse mammary epithelial cell line ATTC – CRL-1636™
MCF-7 Human ER+ breast cancer cell line ATTC – HTB-22™
HDT, hormone-dependent tumor; HIT, hormone-independent tumor; TPC, tumor primary culture; MMTV, mouse mammary tumor virus; ER, 
estrogen receptor, ATCC®, American Type Culture Collection Number.Breast Cancer Research    Vol 9 No 5    Quaglino et al.
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were incubated for 1 hour with a 1:500 dilution of Cy3-conju-
gated affiniPure donkey anti-rabbit IgG (1.5 mg/ml; Jackson
Immunoresearch Laboratories, West Grove, PA, USA).
Cells were mounted and observed under an Olympus
Fluoview FV300 Confocal Laser Scanning Biological
Microscope. Images were analyzed by using Adobe Pho-
toshop (Adobe Systems, Inc., New York, NY, USA).
Protein extraction
Total proteins were extracted from frozen mammary glands,
frozen tumor tissue or cell lines in RIPA protein extraction
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-
100, 0.25% sodium deoxycholate, 1 mM EDTA) supple-
mented with protease (protease inhibitor cocktail set I; Calbi-
ochem) and phosphatase inhibitors (1 mM NaF and 1 mM
Na2VO4). Samples were homogenized and further disrupted
by passage through a 21-gauge needle (8 to 10 times). They
were subsequently incubated on ice for 30 minutes and cen-
trifuged at 9,500 g for 20 minutes at 4°C. Supernatants were
transferred to a fresh tube and the protein concentration was
determined by the Bradford method [29]. Cleared lysates
were combined with SDS sample buffer (50 mM Tris-HCl pH
6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol, 100
mM dithiothreitol), boiled for 8 minutes and resolved by SDS-
PAGE.
Immunoprecipitation
Protein extracts (1.5 mg) from mouse tumors were incubated
with 7 μl of anti-Stat3 (C-20; Santa Cruz Biotechnology) at
4°C overnight, with horizontal rotation. Protein A/G-Sepha-
rose beads (Santa Cruz Biotechnology) were added and incu-
bation continued for a further 2 hours at room temperature.
Samples were then washed three times with PBS and resus-
pended in 10 μl of the previously described sample buffer.
Western blot analysis
Proteins were run on 10% SDS-polyacrylamide gels (80 μg
per lane), blotted to poly(vinylidene difluoride) membranes
(Bio-Rad) and incubated with blocking solution (5% dry
skimmed milk dissolved in TBS-T, 50 mM Tris-HCl pH: 8.8,
150 mM NaCl and 0.1%Tween) for 1 hour. A set of prestained
molecular mass standards was run in each gel. Membranes
were incubated overnight at 4°C with the appropriate dilution
of the following primary antibodies: a rabbit polyclonal anti-
Stat3 antibody (C-20, SC-482), a mouse monoclonal anti-
tyrosine-phosphorylated (pY) Stat3 (SC-8059), a rabbit poly-
clonal anti-ERK (SC-154) and a mouse monoclonal anti-pY-
ERK (SC-7383). All antibodies were purchased from Santa
Cruz Biotechnology. Membranes were washed with TBS-T
before incubation with horseradish peroxidase-conjugated
anti-mouse or anti-rabbit secondary antibodies (Santa Cruz
Biotechnology). Immunoreactive protein bands were detected
by enhanced chemiluminescence (ECL+Plus System; Amer-
sham Biosciences).
RNA analysis
Mammary gland and mammary tumor RNA was obtained using
the SV Total RNA Isolation System (Promega, Madison, WI,
USA) in accordance with the manufacturer's instructions. RNA
from cell lines and primary cultures was obtained with Trizol
(Invitrogen). For Northern blot analysis, poly(A) RNA was
obtained and processed as described previously [17]. For RT-
PCR analysis, cDNA was generated from 2 μg of total RNA
using Moloney murine leukemia virus reverse transcriptase
(Promega), 10 μl of reverse transcription buffer, oligodeox-
ythymidylic acid primer, 25 mM deoxynucleoside triphos-
phates mix and RNase inhibitor (Promega) in a final reaction
volume of 20 μl (60 minutes at 40°C followed by 5 minutes at
90°C). The primers and amplification protocol used in detect-
ing LIF, LIF-R and actin expression have been reported previ-
ously [17]. For gp130, the sense and antisense primers used
were 5'-TCGGAGGAGCGGCCAGAAGAC-3' and 5'-
ATCAGCCCCCGTGCCAAGAGC-3', respectively. For
CCAAT-enhancer-binding protein (C/EBP)δ, the sense and
antisense primers used were 5'-ACCCGCGGCCTTC-
TACGA-3' and 5'-CGCCCCTTTTCTCGGACTGT-3', respec-
tively. Products were subjected to electrophoresis in 2%
agarose gels. For detection of LIF-M and LIF-D expression, the
sense primer sequence for LIF-M was 5'-TGGAAAGCTGT-
GATTGGCGCGAGA-3' and that for LIF-D was 5'-
TGGAGTCCAGCCCATAATGAAGGT-3' ; in both cases a
primer from exon 3 was used (5'-TGGAGTCCAGCCCAT-
AATGAAGGT-3') and the PCR was performed with 35 ampli-
fication cycles. The products were subjected to
electrophoresis on 2% agarose gel.
Real-time PCR data were acquired and analyzed with an Opti-
con Monitor System (MJ Research, Bio-RAD, Hercules CA,
USA) and each amplification mixture was performed in 3.5 mM
MgCl2, 4 μM forward primer, 4 μM reverse primer, 1:30,000
SYBR Green (Invitrogen) with the previously described RT-
PCR kit and protocols [17] but using 35 amplification cycles.
All samples were analyzed for actin expression in parallel in the
same run. For each sample, the amplification plot and the cor-
responding dissociation curves were examined. The specificity
of the amplified product was monitored by examining the melt-
ing curve and the melting peak of the product. The absence of
nonspecific amplification was confirmed for each gene by ana-
lyzing the PCR amplification products by agarose gel electro-
phoresis. To estimate mRNA expression, calibration curves
were made. Experiments were always run in duplicate and
repeated at least twice.
Cell viability assays
Cell viability was evaluated by staining with crystal violet as
described previously [30]. In brief, cells were treated as indi-
cated and fixed with 1.1% glutaraldehyde at the end of each
experiment. After being washed with deionized water and
dried in air, plates were stained with a 0.1% crystal violet solu-
tion. The bound dye was solubilized with 10% acetic acid andAvailable online http://breast-cancer-research.com/content/9/5/R69
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quantified at 590 nm in a Benchmark microplates reader (Bio-
Rad Laboratories, Hercules, CA, USA).
Results
Expression of leukemia inhibitory factor (LIF) and LIF 
receptor in mouse mammary tumor cells
First, LIF expression was analyzed in MMTV(LA) induced
HDTs and HITs (see Table 1) [24,25,31]. When the LIF mRNA
content from different HDTs (n = 3) and HITs (n = 3) was com-
pared with lactating and involuting normal mammary glands,
we found (by quantitative RT-PCR) that this cytokine was
expressed in all these tumors, although its level varied
between them independently of its dependence on hormone
(Fig. 1a). These results were confirmed by Northern blot anal-
ysis (data not shown). Because it has been demonstrated that
there are two alternatively spliced LIF transcripts that originate
two differentially localized LIF proteins, a secreted 'free' form
(LIF-D) and an extracellular matrix-associated one (LIF-M) [32],
their presence was analyzed by RT-PCR with specific sets of
primers. Our results show that both the LIF-D and LIF-M tran-
scripts are present in mammary tumors and involuting glands
(Fig. 1b). To determine the relevance of autocrine LIF in mam-
mary cells, the expression of LIF and LIF-R was determined by
RT-PCR in HDTs, HITs, their primary cultures, and mouse
(non-tumorigenic and tumorigenic) and human (tumorigenic)
mammary cell lines (NmuMG, HC11, SCp2, LM3, LMM3 and
MCF-7; Table 1). We found that all those cells express LIF,
although tumor cells tend to show higher levels than non-tum-
origenic ones. Interestingly, LIF-R was also present in all cell
lines tested, with the exception of LM3 and LMM3 (Fig. 1c).
LIF expression and Stat3 localization analysis; 
histological studies
Morphologically, MMTV(LA)-induced tumors are classical ade-
nocarcinomas with various grades of differentiation. Figure 2a
shows an example of a moderately differentiated HIT with
many cystic papillary areas. Although these tumors also show
poorly differentiated solid regions, round epithelial cells form-
ing small glandular structures could be observed in these
areas (Fig. 2a, inset). In contrast, LM3 tumors are poorly differ-
entiated adenocarcinomas with large tumor cells and hyper-
chromatic nuclei. They also show an abundant vascular stroma
that contains many fibroblasts, neutrophils, lymphocytes,
plasma cells, and occasionally mast cells (Fig. 2b). Apoptotic
images and extensive hemorrhagic necrosis are also seen. In
addition, because of the fusiform feature and swirled disposi-
tion of some cells, there are areas with a sarcomatous appear-
ance (Fig. 2b, inset).
LIF expression has been tested by immunohistochemistry in
HITs and in LM3 tumors (Table 1). In both cases, LIF staining
was predominantly epithelial, although some positive stromal
cells could be seen (Fig. 2c, d). The expression of LIF in invo-
luting and lactating mammary glands is shown as a positive
and a negative control, respectively (Fig. 2e, f).
To determine the level of Stat3 activation in HITs and LM3
tumors, its intracellular localization has been determined by
immunohistochemical analysis. Whereas in HITs the images
show positive staining in epithelial and stromal nuclei (Fig. 2g);
in LM3 tumors Stat3 staining was detected mostly in the cyto-
plasm of epithelial cells (Fig. 2h), which indicates a lack of
Stat3 activation in these tumors. This observation was con-
firmed by Western blot analysis: all the analyzed HITs showed
Figure 1
Expression of LIF and LIF receptor mRNA in mammary tumor cells Expression of LIF and LIF receptor mRNA in mammary tumor cells. (a) 
Real-time PCR showing relative expression levels of leukemia inhibitory 
factor (LIF) in hormone-dependent (HDT) and hormone-independent 
(HIT) mouse mammary tumors compared with lactating (Lac) and 48-
hour involuting (Inv) normal mammary glands. All samples were ana-
lyzed and normalized to actin expression in parallel in the same real-
time PCR assay. (b) Ethidium bromide stained gel showing RT-PCR 
analysis of two different LIF splicing variants: LIF-M and LIF-D. (c) 
Ethidium bromide stained gel showing LIF and LIF-R expression by RT-
PCR in HDT, HIT and in culture growing mammary cell lines: NMuMG, 
HC11, SCp2 (epithelial non-tumorigenic), MCF-7, LM3, LMM3 (tumori-
genic mammary cell lines) and mammary tumor primary cultures (TPC).Breast Cancer Research    Vol 9 No 5    Quaglino et al.
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much higher levels of pY-Stat3 than LM3 tumors (Fig. 3a).
These results suggest that the lack of LIF-R expression results
in a much lower activation of Stat3 in the LM3 tumors.
Tyrosine phosphorylation of Stat3 in culture
For further analysis of the hypothesis that LIF-mediated signal-
ing would be a determinant for Stat3 activation in mouse mam-
mary tumors, the capacity of LIF to induce tyrosine
phosphorylation of Stat3 was analyzed in cultured cells. Our
results show that LIF was able to induce transient Stat3 acti-
vation in HC11 and TPC cells, achieving the highest level of
tyrosine phosphorylation after 15 minutes. However, no pY-
Stat3 was observed in LIF-treated LM3 cells (Fig. 3b, c).
To determine the integrity of the gp130/JAK/Stat3 signaling
pathway in LM3 cells, gp130 expression and the capacity of
Figure 2
Morphological and immunohistochemical analysis of MMTV(LA)-induced HIT and LM3 mammary tumors growing in vivo Morphological and immunohistochemical analysis of MMTV(LA)-induced HIT and LM3 mammary tumors growing in vivo. (a, b) Hematoxylin/eosin-
stained tumors. (a) Moderately differentiated hormone-independent tumors (HIT). Papillary formations into lumen of cystic ducts and less differenti-
ated zones with small glandular structures. Original magnification ×100; inset ×400. (b) LM3 poorly differentiated adenocarcinoma with abundant 
infiltrated vascular stroma. Areas with sarcomatous appearance and apoptotic images (black arrowheads). Original magnification in (a, b) ×100; 
inset ×400. (c-f) Leukemia inhibitory factor (LIF) immunohistochemistry. (c) HIT: heterogenous and regular distribution mainly in poorly differentiated 
areas with cytoplasmic and nucleic positive staining; intense cytoplasmic staining increasing peripherally indicates a secretory pattern (arrowhead). 
(d) LM3 tumor: patchy LIF staining. Inset: positive cytoplasmic staining; the ill-defined cell membrane pattern with granular cytoplasmic staining indi-
cates LIF secretion (arrowhead). (e) Involuting (48-hour) and (f) lactating mammary glands were used as positive and negative controls, respectively, 
for LIF staining. Original magnification in (c-f) 250×; inset: 400× (g, h) Stat3 (signal transduction and activators of transcription 3) immunohisto-
chemistry. (g) HIT: stromal and predominantly epithelial positive nuclear staining in solid areas. Inset: stained nuclei were also seen in glandular 
regions. (h) LM3 tumor: intense cytoplasmic positive staining in stromal and epithelial cells. The inset shows a negative gland surrounded by positive 
stromal cells. Original magnification in (g, h) 250×; inset: 400×Available online http://breast-cancer-research.com/content/9/5/R69
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another LIF-family cytokine to induce Stat3 phosphorylation
was evaluated. We found similar levels of gp130 mRNA in all
cells tested (HC11, TPC and LM3; data not shown). In addi-
tion, IL-6-treated LM3 cells showed a significant level of pY-
Stat3 (Fig. 3d). This suggests that the lack of Stat3 activation
in LIF-treated LM3 cells was due to a deficiency in LIF-R
expression and not to the impairment of another component of
the gp130/JAK/Stat3 signaling cascade.
We next investigated the capacity of TPC CM to induce Stat3
phosphorylation in mammary cells. Our results show that CM
induced Stat3 phosphorylation in HC11 cells (Fig. 4a, upper
panel). Interestingly, this treatment was unable to induce Stat3
activation in LM3 cells (Fig. 4a, lower panel). A LIF blocking
antibody was then used to determine whether this cytokine
was responsible for the CM-induced Stat3 activation. Our
results show a clear inhibition of this activity in HC11 and TPC
cells (Fig. 4b). Notably, this antibody was unable to completely
block the capacity of LIF (3 to 5 ng/ml) to induce Stat3 phos-
phorylation in HC11 cells (Fig. 4c). The remaining Stat3 acti-
vation observed in cells treated with CM plus LIF-blocking
antibody could therefore still have been due to residual LIF
activity in the presence of this antibody. These results indicate
that locally produced LIF exerts a major role on Stat3 tyrosine
phosphorylation in mammary tumors.
To determine whether Stat3 tyrosine phosphorylation induced
by CM resulted in transcriptional activation of this factor, we
assessed the expression of a known transcriptional target of
Stat3, namely C/EBPδ [33]. Our results show that LIF as well
as CM induces C/EBPδ transcription in mammary tumor cells
and that CM-dependent C/EBPδ induction was inhibited by
pretreatment with LIF-blocking antibody (Fig. 4d).
It has been reported that the IL-6 cytokine family is able to
induce Stat3 activation through the gp130 receptor by using
an 'unconventional' signaling route that involves ERK1/2 phos-
phorylation [34]. The ability of LIF to induce this mitogen-acti-
vated protein kinase (MAPK) activation was then evaluated in
HC11 cells. LIF (5 ng/ml) induced a detectable activation of
ERK1/2 that disappeared in the presence of LIF-blocking anti-
body (Fig. 4c). However, the use of a MAPK/ERK kinase
(MEK)-specific inhibitor (PD98059) completely blocked LIF-
induced ERK1/2 activation but did not affect the induction of
Stat3 tyrosine phosphorylation (Fig. 4e). These results indi-
cate that the ERK1/2 activation achieved with 5 to 20 ng/ml
LIF does not exert a major effect on Stat3 activation in HC11
cells. In addition, PP2, a selective inhibitor of Src family of pro-
tein tyrosine kinases, had no effect on LIF-induced Stat3 tyro-
sine phosphorylation in mammary cells (Fig. 4f), suggesting
that this effect would not depend on Src activation.
Figure 3
Western blot analysis of phospho-Stat3 (pStat3) and Stat3 Western blot analysis of phospho-Stat3 (pStat3) and Stat3. (a) Tumors 
growing in vivo: LM3 (lane 1) and different HIT transplants (lanes 2 to 
5). (b-d) Cells growing in culture. (b) HC11, LM3 and tumor primary 
culture (TPC) cells treated with 80 ng/ml leukemia inhibitory factor (LIF) 
for 15 minutes; mammary glands at 48 hours of involution (Inv) and at 
fifth day of lactation (Lac) were used as positive and negative controls, 
respectively. (c) Time course of tyrosine phosphorylation of Stat3 (sig-
nal transduction and activators of transcription 3) in HC11 cells (upper 
panel) and TPC cells (lower panel) treated with 80 ng/ml LIF. (d) Tyro-
sine phosphorylation of Stat3 in HC11 and LM3 cells treated with LIF 
and IL-6 (both at 80 ng/ml) for 15 minutes.Breast Cancer Research    Vol 9 No 5    Quaglino et al.
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To analyze the biological activity of LIF on mouse mammary
tumor and non-tumor cells, we evaluated the effect of this
cytokine on the survival of HC11, TPC and LM3 cells. We
have found that 72 hours of LIF treatment induced a dose-
dependent inhibition of HC11 cell survival, whereas it also
caused a dose-dependent increase in the number of viable pri-
mary tumor cells. As expected, no effect was observed in LIF-
treated LM3 cells (Fig. 5a). Similarly, CM induced opposite
effects on the viability of HC11 and TPC cells; these were pre-
vented by pretreatment with a LIF-blocking antibody (Fig. 5b).
Then, to determine whether Stat3 and/or ERK1/2 activation
were involved in the effect of LIF on cell survival, HC11 and
TPC cells were treated with this cytokine for 72 hours in the
presence or absence of Stat3ip or PD98059. As expected,
the inhibitory effect of LIF on the survival of HC11 cells was
blocked by Stat3ip. Interestingly, this treatment did not inhibit
the stimulatory activity of LIF on TPC cell survival; instead, it
significantly enhanced it (Fig. 5c). In contrast, blocking ERK1/
2 activation had a marked inhibitory effect on TPC cell survival,
whereas the same assay produced a much milder response in
HC11 cells (Fig. 5f). As has previously been reported by oth-
ers, we confirmed the inhibitory capacity of Stat3ip (1 mM) by
analyzing its ability to interfere with LIF-induced Stat3 phos-
phorylation (Fig. 5d) [35] and nuclear translocation (Fig. 5e)
[36]. Therefore, the different biological activity displayed by
LIF on normal cells and tumor cells might be due to the altered
biological response that tumor cells develop to the activation
of certain signaling pathways rather than to a differential effect
of this cytokine on its intracellular mediators.
Figure 4
Effect of tumor primary culture (TPC) conditioned medium (CM) and leukemia inhibitory factor (LIF)-neutralizing antibody Effect of tumor primary culture (TPC) conditioned medium (CM) and leukemia inhibitory factor (LIF)-neutralizing antibody. (a) Stat3 (signal transduc-
tion and activators of transcription 3) and phospho-Stat3 (p-Stat3) in HC11 and LM3 cells treated with increasing concentrations of CM (30%, 50% 
and 80%). (b) Stat3 and p-Stat3 levels in HC11 and TPC cells treated with CM that had been preincubated with or without LIF-neutralizing anti-
body. (c) Phosphorylation levels of Stat3 and extracellular signal-regulated kinase (ERK)1/2 in HC11 cells treated with LIF (3 and 5 ng/ml) preincu-
bated with or without LIF-neutralizing antibody. (d) Expression of CCAAT-enhancer-binding protein (C/EBP)δ in TPC cells treated with CM with or 
without neutralizing antibody. (e) Phosphorylation of Stat3 and ERK1/2 in HC11 cells treated with LIF with or without the MAP kinase/ERK kinase 
inhibitor PD98059. (f) p-Stat3 and Stat3 in HC11 and TPC cells treated with LIF with or without the Src-specific inhibitor PP2. Experiments were 
repeated at least three times with similar results. No effect was observed on phosphorylation levels of either Stat3 or ERK1/2 when HC11 cells were 
treated with the PD98059 vehicle, dimethyl sulfoxide (data not shown).Available online http://breast-cancer-research.com/content/9/5/R69
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Figure 5
Effect of LIF and CM on cell viability after 72 hours of treatment Effect of LIF and CM on cell viability after 72 hours of treatment. Viability was assessed by crystal violet assays. (a) HC11, tumor primary culture 
(TPC) and LM3 cells were treated with leukemia inhibitory factor (LIF; 20 and 50 ng/ml). (b) HC11 and TPC cells were treated with 50% condi-
tioned medium (CM) preincubated with or without LIF-neutralizing antibody. (c) HC11 and TPC cells were treated with 50 ng/ml LIF in the presence 
or absence of a Stat3 (signal transduction and activators of transcription 3) inhibitor peptide. (d, e) Effect of Stat3-specific inhibitory peptide 
(Stat3ip) on Stat3 phosphorylation levels (d) and nuclear translocation (e) induced by LIF. 400× (f) HC11 and TPC cells were treated with 50 ng/ml 
LIF in the presence or absence of PD98059. Data are percentages of internal control for each cell type (time 0) and are expressed as means ± SEM 
for four replicates. Experiments were repeated at least three times with similar results. Asterisk denotes statistical difference (P < 0.05) in a two-
tailed Student's t test.Breast Cancer Research    Vol 9 No 5    Quaglino et al.
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Discussion
Activation of Stat3 has been detected in many human neopla-
sias [37,38], and it has been shown that IL-6-type cytokines
induce Stat3 phosphorylation in various human and rodent cell
lines [21,23]. In addition, it has been demonstrated that these
cytokines, including LIF, are expressed in breast cancer cells
and in other tumor types [4,39]. Interestingly, in certain mye-
loma and prostate cancer cell lines, IL-6 has been identified as
the main cytokine responsible for Stat3 activation induction
[40,41]. In addition, a very recent report suggests a similar role
for this cytokine in breast cancer cells [42]. In mouse mam-
mary glands during post-lactational involution, both induction
of IL-6 and LIF expression and Stat3 activation have been
demonstrated [17,18,34]. Interestingly, in this context, Stat3
activation seems to be more dependent on LIF than on IL-6
status [43]. In mammary tumors, to our knowledge, no report
has yet been made linking LIF expression to Stat3 activation.
It has been reported that LIF and LIF-R expression in breast
tumors is associated with favorable biological features such as
diploidy and low S-phase fraction. In addition, in those tumors
LIF-R expression was correlated with the presence of ER [3].
On the basis of these data, those authors postulated that
tumors expressing LIF/LIF-R would represent a phenotype that
is closer to 'normal' and would therefore be less aggressive.
Interestingly, although it has been shown that Stat3
expression and activation is commonly found in breast cancer
cells [15], and this transcription factor activation resulted in
the malignant transformation of fibroblasts [43] and the prolif-
eration of mammary tumor cells [4,6,44,45], there is also evi-
dence that Stat3 activation in human breast cancer is
associated with a better prognosis [46].
Our results in mouse mammary tumors also show an associa-
tion between LIF-R expression and Stat3 activation with a less
aggressive phenotype. LIF-R+  MMTV(LA)-induced tumors
appear in mid-pregnancy, when serum progesterone and
estrogen levels are high, and continue to grow until delivery.
After this, they soon regress and reappear in subsequent ges-
tations, suggesting that progesterone and/or estrogen have a
main role in their development. In addition, these tumors show
high expression of estrogen and progesterone receptors
(ER+PR+). Eventually, in the same mouse or after successive
passages, these neoplasias progress to become autonomous:
they lose hormone receptor expression and grow independ-
ently of the female's hormonal status [24]. However, in spite of
this drastic change in hormone dependence, MMTV(LA) HITs
are not very aggressive and show a variety of histological pat-
terns, from well-differentiated to very poorly differentiated
architecture [24]. They also remain LIF responsive and show
Stat3 activation. In contrast, the LM3 cell line, which derives
from a spontaneous BALB/c mammary adenocarcinoma,
gives rise to ER-  PR-  poorly differentiated highly invasive
(100% incidence of lung metastasis) tumors [47]. Here we
have shown that these tumors do not express LIF-R and show
low levels of Stat3 activation. Our results from mouse mam-
mary tumors are therefore in good agreement with data from
human breast cancer samples. This suggests that, in certain
cases, these experimental models can be better tools than
breast cancer cell lines for reproducing particular aspects of
human malignancies.
In transformed cells, there are no known naturally occurring
mutations in Stat3 that lead to its constitutive activation. Alter-
natively, it has been proposed that Stat3 activation in tumors
and in oncogene-transformed cells would be dependent on
growth factor tyrosine kinase receptor activation or deregula-
tion of JAK kinase's activity [48]. The results shown here dem-
onstrate that in well-differentiated mouse mammary tumors the
constitutive activation of Stat3 would be mostly dependent on
overexpression of LIF. The phosphorylation regulatory path-
ways of this transcription factor might therefore not be altered
in these cancer cells. In addition, it has been shown that block-
ing ERK1/2 phosphorylation resulted in inhibition of Stat3 acti-
vation in Jak2-null cells, whereas no effect on pY-Stat3 has
been observed in wild-type cells [43]. Similarly, in HC11 cells
we have not found a clear effect on Stat3 tyrosine phosphor-
ylation when ERK1/2 activation was blocked. These results
suggest that this MAPK could have a relevant role in mammary
Stat3 activation only when the gp130/Jak2 pathway has been
impaired in some way.
Our results from the crystal violet assays indicate that treat-
ment with LIF can produce different biological responses in
non-tumorigenic and tumorigenic cells, namely inhibiting and
inducing cell survival, respectively. However, and in spite of
this cytokine's being the principal one responsible for Stat3
phosphorylation, in both cases blocking Stat3 activation
increased cell survival. It has been shown that expression of
the phosphoinositide 3-kinase regulatory subunits p55α and
p50α is directly induced by Stat3 during mammary gland invo-
lution [18]. These proteins are involved in the downregulation
of phosphoinositide 3-kinase signalling and Akt/protein kinase
B activity, and abrogation of this survival pathway is essential
for the induction of apoptosis in mammary epithelial cells [18].
Our interpretation for the results shown here is therefore that
in certain mammary tumor cells this apoptosis-inducing path-
way is still functioning. However, these cancer cells are not
fully responsive to the strategies for controlling cell survival
because they are very sensitive to the activation of proliferative
signaling pathways. For example, our results show clearly how
much more susceptible tumor cells are to inhibition of MEK
activity. We therefore believe that in both normal and neoplas-
tic mammary cells LIF is able to induce both the survival and
apoptotic pathways, the balance of which can lead to com-
pletely different outcomes in these cell types.
Stat3 biological activity depends on multiple factors, many still
unknown. For example, in melanoma cells, IL-6/Stat3 function
is modulated by the stage of tumor progression [49]. TheAvailable online http://breast-cancer-research.com/content/9/5/R69
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results shown here suggest that in well-to-moderately differen-
tiated mammary tumor cells, LIF-induced Stat3 activation pre-
serves the pro-apoptotic role of this factor in non-tumorigenic
mammary cells. This activity might be altered in more
aggressive or less differentiated tumors by different causes
that need to be analyzed in future experiments. However, our
results imply that in the development of therapeutic strategies
for blocking Stat3 in breast cancer cells, the strong depend-
ence on the cellular context that this factor activity displays
should be taken into account.
Conclusion
The results presented here show that LIF is overexpressed in
MMTV-induced mammary carcinomas, in which, as a para-
crine/autocrine factor, it is the main one responsible for Stat3
activation. In well-differentiated mammary cancer cells, consti-
tutive activation of Stat3 would therefore depend on LIF and
LIF-R expression, as occurs in normal mammary epithelium.
However, in these cancer cells, LIF induces cell survival
through signaling pathways that would not involve Stat3
activation.
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